InVivo Therapeutics (NVIV) Upgraded by Zacks to OUTPERFORM
Zacks Investment Research upgraded shares of InVivo Therapeutics (NVIV) from NEUTRAL to OUTPERFORM on January 21, 2015, with a target price of $3.25. On January 21, 2015, InVivo Therapeutics (NVIV) provided an update on the status of the first patient enrolled in the company's ongoing pilot study of its investigational Neuro-Spinal Scaffold (NSS) for the treatment of acute spinal cord injury. The primary safety endpoint will be assessed again at six months, but things look to have gone well with respect to the key gating-factor to moving forward with enrolling more patients in the study […]